BEUDAMED
    FDA Adverse Event Injury Summary report: N

    GELSYN-3 16.8 MG/2ML SYR (2=1)

    MDR report key: 14488400 · Received May 23, 2022

    Report

    Report Number
    MW5109858
    Event Type
    Injury
    Date Received
    May 23, 2022
    Report Date
    May 20, 2022
    Manufacturer
    IBSA FARMACEUTICI ITALIA SRL
    Product Code
    MOZ
    Adverse Event
    Yes
    Report Source
    Voluntary report
    Reporter Location
    PA, US
    Reporter Occupation
    OTHER HEALTH CARE PROFESSIONAL
    Health Professional
    Yes

    Narratives

    Description of Event or Problem · 0

    PT REPORTED HAVING MACULAR DEGENERATION. INJECT 1 SYRINGE INTRA-ARTICULARLY IN THE RIGHT KNEE ONCE PER WEEK FOR 3 WEEKS.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    150534 GELSYN-3 16.8 MG/2ML SYR (2=1) ACID, HYALURONIC, INTRAARTICULAR MOZ IBSA FARMACEUTICI ITALIA SRL

    Patients

    Seq Age Sex Outcome Treatment
    1 Female